Literature DB >> 8789009

Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA.

H J Lin1, M Haywood, F B Hollinger.   

Abstract

Quantitative tests for human immunodeficiency virus type 1 (HIV-1) RNA in plasma and proviral DNA in peripheral blood mononuclear cells (PBMC) provide valuable information on the status of HIV-1 infection. This paper describes tests that were carried out with commercially available materials and an enzyme-linked immunosorbent assay reader for detecting spectrophotometric changes. Samples consisted of 100 microliters of plasma or 200,000 PBMC. The procedure involved sample preparation, PCR-based amplification with the primer pair SK39 (biotinylated at the 5' end) and SK38, hybridization of the cDNA PCR product to an RNA probe, capture of the RNA-DNA hybrid on a solid phase by means of strepavidin, binding to an alkaline phosphatase-conjugated antibody directed against RNA-DNA hybrids, and incubation with p-nitrophenylphosphate. Spectrophotometric changes were recorded at four intervals over a period of 20 h. The inclusion of HIV-1 RNA or proviral DNA standards in each run was an integral part of the procedure. The dynamic ranges afforded by these assays--500 to 1 million RNA copies per ml and 10 to 5,000 proviral DNA copies per 10(6) PBMC--were applicable to most plasma specimens and to all PBMC specimens from HIV-1-infected patients. Correlations of log-transformed HIV-1 RNA and proviral DNA concentrations with those found by reference methods were, respectively, 0.88 and 0.80. The between-run coefficients of variation for the detection method were < or = 25% (range, 9.1 to 24.7) and < or = 15% (range, 10.9 to 15.1), respectively, for HIV-1 RNA and proviral DNA. The reproducibility of the overall procedure for HIV-1 RNA in plasma (including sample preparation, amplification, and detection) was given by a duplicate standard deviation of log10 copies per ml of 0.11. Thus, the method was sufficiently precise to allow the detection of fourfold changes in plasma HIV-1 RNA concentrations, with a power of 0.95.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789009      PMCID: PMC228791          DOI: 10.1128/jcm.34.2.329-333.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Comparison of three nonradioisotopic polymerase chain reaction-based methods for detection of human immunodeficiency virus type 1.

Authors:  A J Whetsell; J B Drew; G Milman; R Hoff; E A Dragon; K Adler; J Hui; P Otto; P Gupta; H Farzadegan
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Limitations and modifications of quantitative polymerase chain reaction. Application to measurement of multiple mRNAs present in small amounts of sample RNA.

Authors:  J S Babu; S Kanangat; B T Rouse
Journal:  J Immunol Methods       Date:  1993-10-15       Impact factor: 2.303

Review 3.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

4.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

5.  Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories.

Authors:  J B Jackson; J Drew; H J Lin; P Otto; J W Bremer; F B Hollinger; S M Wolinsky
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

6.  Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.

Authors:  P Bagnarelli; S Menzo; A Valenza; S Paolucci; S Petroni; G Scalise; R Sampaolesi; A Manzin; P E Varaldo; M Clementi
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

7.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.

Authors:  H J Lin; L E Myers; B Yen-Lieberman; F B Hollinger; D Henrard; C J Hooper; R Kokka; S Kwok; S Rasheed; M Vahey
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

10.  Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction.

Authors:  M A Winters; L B Tan; D A Katzenstein; T C Merigan
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

View more
  3 in total

1.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

2.  Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  F S Nolte; J Boysza; C Thurmond; W S Clark; J L Lennox
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

3.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.